Cytrellis Biosystems Secures $28.5M Series B Financing Led by ARCH Venture Partners to Advance Scarless Skin Tightening Technology

VCBeat (WeChat: vcbeat) has learned that in early June, medical aesthetics technology company Cytrellis Biosystems completed a $28.5 million Series B financing round. Investors included previous backers ARCH Venture Partners and the Merz Venture Initiative, as well as new investors Partner Fund Management and BioMatics Capital.

The Company’s Three Female Co-Founders

Upon completion of the financing, Michael Peterson, Chief Technology Officer of a device company under Merz Venture Initiative, will join the board of directors.

“We are pleased to close this important financing round, which will enable the company to complete subsequent clinical studies and fund our regulatory approvals,” said Karen Cronholm, President and Chief Executive Officer of Cytrellis. “In addition, we welcome Mr. Peterson for his provision of specialized technical expertise; he has been instrumental in leading the development of multiple dermatological devices, including the well-known Ultherapy® and Cellfina®.”

Data shows that Cytrellis Biosystems, based in Massachusetts, USA, has developed proprietary micro-excision skin technology, which pioneers a novel approach to dermatological treatment beyond energy-based devices and surgical procedures.

What makes this technology particularly unique is that it does not rely on traditional energy-based therapies. While photoelectric methods can be employed to attempt repair of damaged skin, their efficacy is limited or requires prolonged healing times, and they cannot significantly reduce or eliminate skin laxity. Consequently, patients must undergo surgical procedures to remove excess skin and mitigate sagging.

According to statistics from the American Society for Aesthetic Plastic Surgery (ASAPS), Americans spent over $15 billion on cosmetic procedures in 2016, an 11% increase from 2015. Despite advancements in the medical aesthetics industry over the past decade, there remains no non-surgical method capable of removing unwanted skin without scarring.

Cytrellis Biosystems is not based on the currently mainstream optoelectronic

Cytrellis System, comprising a handheld device and consumables, treats large areas of facial skin in a precise and user-friendly manner. The device also features a skin coring mechanism that enables precise control over the location and depth of micro-incisions.

According to official website data, 80 participants showed favorable skin tissue healing 90 days after undergoing this minimally invasive procedure. The pain level during treatment was 0.36, indicating very mild discomfort, and the overall satisfaction rate with the improvement outcomes reached 93%.

Cytrellis: 90-Day Clinical Outcomes

Following this round of financing, the company will further advance its clinical research programs to obtain regulatory approvals.

Cytrellis Biosystems is a medical technology company developing innovative aesthetic devices designed to eliminate age-related skin laxity without surgery or scarring, enabling consumers to improve their skin condition and restore a youthful appearance. According to available information, Cytrellis is committed to collaborating with leading dermatologists and plastic surgeons to develop unique product solutions that emphasize safety, clinical efficacy, and improvements in quality of life.

For over 30 years, ARCH Venture has focused on investments in the life sciences sector. During this period, it has participated in more than 250 investment deals. Well-known companies such as CRAIL, Illumina, Kythera Biopharmaceuticals, WuXi AppTec, Juno Therapeutics, and Erythromycin Biopharma are among its portfolio companies. Renowned for its bold investment strategy, ARCH Venture has consistently focused on medical technologies and unmet medical needs.